Αρχική World News Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma

Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma

Findings from a propensity-matched survival analysis presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020, suggest that patients with advanced melanoma and a BRAFV600 mutation derive an enhanced survival benefit from first-line treatment with anti-PD-1 monotherapy, as compared to BRAF/MEK inhibitors.

Jesper van Breeschoten of the Scientific Department, Dutch Institute for Clinical Auditing in Leiden, Netherlands and department of medical oncology Amsterdam UMC, Netherlands,  explained that currently the data are inconclusive on whether to use anti-PD-1 monotherapy or BRAF/MEK inhibitors as first-line treatment in patients with advanced BRAFV600-mutant melanoma, prompting this propensity score matching study, which compared the two types of agents in this patient population.  

The investigators identified patients diagnosed with unresectable stage III or IV melanoma who had a known BRAFV600-mutation and were registered in the Dutch Melanoma Treatment Registry. From 2014 to 2017, a total of 254 of these patients received first-line treatment with anti-PD-1 monotherapy and 330 received first-line treatment with BRAF/MEK inhibitors. Of these, 310 patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method for inclusion in the matched cohort.

Overall survival favoured immune checkpoint inhibitor as first-line therapy for patients with BRAFV600-mutant advanced melanoma

Comparison of these two first-line treatment strategies in the matched cohort showed that patients receiving anti-PD-1 antibodies demonstrated a higher median and 12-month overall survival (OS) compared to patients treated with first-line BRAF/MEK inhibitors.  

Median OS was 42.3 months (95% confidence interval [CI] 37.3-not estimable) with anti-PD-1 monotherapy compared to 19.8 months (95% CI 16.7-24.3) with BRAF/MEK inhibition in the matched cohort. The 24–month OS rates were 64.00% (95% CI 58.2-70.4) compared to 41.7% (95% CI 34.2-51.0), with the respective treatments.

Full results are accepted for publication in the British Journal of Cancer.

Conclusions

The authors concluded that these data suggest that anti-PD-1 monotherapy is the preferred first-line treatment in matched patients with BRAFV600-mutant advanced melanoma and relatively favourable patient and tumour characteristics.

They await results from currently ongoing randomised clinical studies to confirm this finding.

No external funding was disclosed for this analysis.

Reference

37P – Breeschoten JV, Wouters M, Hilarius D, et al. First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field...

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

The right combination for early detection

The upcoming Early Detection of Cancer Conference brings together experts from multiple disciplines to share ground breaking research and progress in the field. Here...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...